CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

FDA Recommends Orphazyme Provides Supplemental Information and Analyses FDA Offers to have Further Interactions with Orphazyme to Identify Path to Resubmission for Arimoclomol in NPC CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a spe